Today's Daily Dose brings you news about Acorda's progress with its Parkinson's therapy Inbrija; Alkermes' encouraging results from its ENLIGHTEN-1 study; FDA approval for expanded use of Amgen's Vectibix in wild-type RAS metastatic colorectal cancer and Cara's disappointing results from its phase IIb trial of CR845 in patients with osteoarthritis of the knee or hip.
from RTT - Biotech http://ift.tt/2snD4BJ
via IFTTT
No comments:
Post a Comment